NCMAG111 Sunitinib advice document: January 2024
Posted on:
Document Type
Process guidance
Summary
Second line treatment of adult patients with poor or intermediate risk advanced/metastatic renal cell carcinoma who have received nivolumab in combination with ipilimumab as first line treatment. (Off-patent use)
Decision: Supported